Stocktoria
Lite Strategy, Inc. LITS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2003-12-18
Lite Strategy, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $65.3M | $48.8M | $40.7M | $34.8M |
| R&D expense | $3.9M | $16.6M | $52.5M | $85.6M | $69.4M |
| Operating income | -$17.5M | $14.5M | -$36.8M | -$75.5M | -$60.4M |
| Income tax | $0 | $0 | $0 | $0 | $8,000 |
| Net income | -$15.9M | $17.8M | -$32.0M | -$54.5M | -$41.3M |
| EPS (diluted) | $-2.39 | $2.67 | $-4.78 | $-9.99 | $-0.60 |
| Operating cash flow | -$20.8M | -$50.5M | -$52.5M | -$48.7M | -$32.0M |
| Free cash flow | -$20.8M | -$50.5M | -$52.5M | -$49.2M | -$32.7M |
| Cash & equivalents | $18.0M | $3.7M | $16.9M | $15.7M | $8.5M |
| Total assets | $18.3M | $41.4M | $120.8M | $177.8M | $174.1M |
| Total liabilities | $1.4M | $8.4M | $96.2M | $125.4M | $124.6M |
| Shareholders' equity | $16.9M | $33.0M | $24.6M | $52.4M | $49.5M |
Source: SEC EDGAR filings · CIK 0001262104 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.